Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Cedars-Sinai Medical Center
- Registration Number
- NCT01157949
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Beverly Hills, California, United States
Hematopoietic Stem Cell Transplant for Fanconi Anemia
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 1
- Registration Number
- NCT01071239
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00990249
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Unrelated Cord Blood Transplantation
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT00916045
- Locations
- 🇬🇧
King's College Hosptial NHS Foundation Trust, London, United Kingdom
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00899431
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 200
- Registration Number
- NCT00859131
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
- Conditions
- Interventions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00813124
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00806598
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT00801931
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
Hematopoietic Stem Cell Transplant in Devic's Disease
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 13
- Registration Number
- NCT00787722
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.